OOIR: Observatory of International Research

Papers

(The H4-Index of European Journal of Medicinal Chemistry is 63. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Oxidative stress mitigation by antioxidants - An overview on their chemistry and influences on health status	393
Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review	302
β-lactam antibiotics: An overview from a medicinal chemistry perspective	287
Alzheimer’s disease and its treatment by different approaches: A review	246
An insight on medicinal attributes of 1,2,4-triazoles	192
Bioactive pyrrole-based compounds with target selectivity	152
A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer’s disease agents: A review	151
RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic	149
Application of sulfoximines in medicinal chemistry from 2013 to 2020	149
Antibacterial activities with the structure-activity relationship of coumarin derivatives	137
Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges	132
Research progress of mTOR inhibitors	130
Small molecule selenium-containing compounds: Recent development and therapeutic applications	130
The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020	123
Toll-like receptor 4 (TLR4) inhibitors: Current research and prospective	112
Synthetic and medicinal perspective of quinolines as antiviral agents	109
Pyrazole-based analogs as potential antibacterial agents against methicillin-resistance staphylococcus aureus (MRSA) and its SAR elucidation	108
Sulfonamide derivatives as potential anti-cancer agents and their SARs elucidation	106
Treatment for liver cancer: From sorafenib to natural products	104
Plant isoquinoline alkaloids: Advances in the chemistry and biology of berberine	104
Quercetin derivatives: Drug design, development, and biological activities, a review	100
Therapeutic strategies to overcome cisplatin resistance in ovarian cancer	93
Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors	91
Drug repositioning: Progress and challenges in drug discovery for various diseases	90
Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update	89

Recent advancements in the development of bioactive pyrazoline derivatives	87
A review: Biologically active 3,4-heterocycle-fused coumarins	86
Current development of CBP/p300 inhibitors in the last decade	84
FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application	83
Camptothecin's journey from discovery to WHO Essential Medicine: Fifty years of promise	82
A review: Pharmacological aspects of metal based 1,2,4-triazole derived Schiff bases	82
Discovery of natural anti-inflammatory alkaloids: Potential leads for the drug discovery for the treatment of inflammation	82
Antimicrobial drugs bearing guanidine moieties: A review	81
A review on the structure and pharmacological activity of phenylethanoid glycosides	81
The application of isatin-based multicomponent-reactions in the quest for new bioactive and druglike molecules	80
Chemotherapy and chemo-resistance in nasopharyngeal carcinoma	79
PROTACs to address the challenges facing small molecule inhibitors	79
1,2,3-Triazole-containing hybrids with potential antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA)	78
Synthetic α-glucosidase inhibitors as promising anti-diabetic agents: Recent developments and future challenges	78
Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment	77
Developments of CRBN-based PROTACs as potential therapeutic agents	76
Recent accomplishments on the synthetic/biological facets of pharmacologically active 1H-1,2,3-triazoles	75
Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies	75
Azithromycin: The First Broad-spectrum Therapeutic	74
Research progress of indole compounds with potential antidiabetic activity	71
Recent advances in the design and discovery of synthetic tyrosinase inhibitors	71
Exosomes from different cells: Characteristics, modifications, and therapeutic applications	70
Chemistry, biosynthesis and biological activity of terpenoids and meroterpenoids in bacteria and fungi isolated from different marine habitats	69
The nano delivery systems and applications of mRNA	68
Potentials of nanotechnology in treatment of methicillin-resistant Staphylococcus aureus	67
Structural insights of oxindole based kinase inhibitors as anticancer agents: Recent advances	67
First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo	67
Anticancer potential of spirocompounds in medicinal chemistry: A pentennial expedition	67
β-Carbolines as potential anticancer agents	67
Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy	67
Pt(II) and Au(III) complexes containing Schiff-base ligands: A promising source for antitumor treatment	67
Chalcones: Unearthing their therapeutic possibility as monoamine oxidase B inhibitors	66
Recent advances in DDR (DNA damage response) inhibitors for cancer therapy	66
A review on ferulic acid and analogs based scaffolds for the management of Alzheimer’s disease	66
A key review on oxadiazole analogs as potential methicillin-resistant Staphylococcus aureus (MRSA) activity: Structure-activity relationship studies	66
Therapeutic progression of quinazolines as targeted chemotherapeutic agents	65
Discovery of potent small molecule PROTACs targeting mutant EGFR	64
Pyridazine as a privileged structure: An updated review on anticancer activity of pyridazine containing bioactive molecules	64
Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: Structural enhancements, increased solubility, and micellar studies	63
Discovery of unique thiazolidinone-conjugated coumarins as novel broad spectrum antibacterial agents	63
Coumarin–benzimidazole hybrids: A review of developments in medicinal chemistry	63
Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems	63